Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: A randomized, placebo-controlled, Phase III study

Vaccine

Volumn 31, Issue 49, 2013, Pages 5814-5821

  HSS, Amar Singh ^a   Koh, Mia Tuang ^b   Tan, Kah Kee ^c   Chan, Lee Gaik ^d   Zhou, Lynn ^e   Bouckenooghe, Alain ^f   Crevat, Denis ^g   Hutagalung, Yanee ^f  

^a HOSPITAL RAJA PERMAISURI BAINUN   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c Hospital Tuanku Jaafar   (Malaysia)

^d SARAWAK GENERAL HOSPITAL   (Malaysia)

^e Biometry China   (China)

^f NONE   (Singapore)

^g SANOFI PASTEUR   (France)

Author keywords

Immunogenicity; Malaysia; Paediatric population; Safety; Suggestions dengue; Vaccine

Indexed keywords

CYD TETRAVALENT DENGUE VACCINE; DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; ASTHENIA; CHILD; CONTROLLED STUDY; DEATH; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INFECTION; INFECTION PREVENTION; INFESTATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALAYSIA; MALE; MYALGIA; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE BLIND PROCEDURE; UPPER RESPIRATORY TRACT INFECTION;

IMMUNOGENICITY; MALAYSIA; PAEDIATRIC POPULATION; SAFETY; SUGGESTIONS DENGUE; VACCINE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS PROTECTION; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; MALAYSIA; MALE; SINGLE-BLIND METHOD; VACCINATION;

EID: 84887608709     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.013     Document Type: Article

References (34)

1. Ooi E-E., Gubler D.J. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saúde Pública 2008, 25(Suppl. 1):S115-S124.
2. World Health Organization, Dengue: guidelines for diagnosis, treatment, prevention and control; 2009. Available from: (last accessed: 19.02.13). http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf.
3. Chow V.T. Molecular diagnosis and epidemiology of dengue virus infection. Ann Acad Med Singapore 1997, 26:820-826.
4. World Health Organization Western Pacific Region, Dengue in the Western Pacific Region; 2013. Available from: (last accessed 19.02.13). http://www.wpro.who.int/emerging_diseases/Dengue/en/index.html.
5. Poovaneswari S. Dengue situation in Malaysia. Malays J Pathol 1993, 15:3-7.
6. World Health Organization, The dengue strategic plan for the Asia-Pacific region 2008-2015; 2008. Available from: (last accessed 19.02.13). http://www.wpro.who.int/mvp/documents/docs/Dengue_Strategic_Plan.pdf.
7. World Health Organization Western Pacific Region Asia-Pacific Dengue Program Managers Meeting 2008.
8. Arima Y., Matsui T. Epidemiologic update of dengue in the Western Pacific Region, 2010. Western Pac Surveill Response J 2011, 2:4-8.
9. Dom N.C., Ahmad A.H., Adawiyah R., Ismael R. Spatial mapping of temporal risk characteristic of dengue cases in Subang Jaya. International conference on science and social research 2003, 361-366.
10. Ministry of Health Malaysia Clinical practice guidelines: management of dengue infection in adults (revised 2nd edition); 2010. Available from: (last accessed 19.02.13). http://www.moh.gov.my/attachments/5502.
11. Ministry of Health Malaysia, Malaysian Ministry of Health: Data on file; 2012.
12. World Health Organization Western Pacific Region, Western Pacific Country Health Information Profiles: 2009 Revision; 2009. Available from: (last accessed 19.02.13). http://www.wpro.who.int/publications/docs/CHIPS2009.pdf.
13. World Health Organization Western Pacific Region, Western Pacific Country Health Information Profiles: 2011 Revision; 2011. Available from: (last accessed 19.02.13). http://www.wpro.who.int/entity/health_information_evidence/documents/CHIPS2011.pdf.
14. Thomas S.J., Endy T.P. Vaccines for the prevention of dengue: development update. Hum Vaccines 2011, 7:674-684.
15. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74:5477-5485.
16. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75:7290-7304.
17. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
18. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010, 6:696-705.
19. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
20. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29:3863-3872.
21. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccines 2006, 2:60-67.
22. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolid O., Zambrano B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30:5935-5941.
23. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
24. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled Phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30:e9-e17.
25. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85:724-731.
26. Leo Y.S., Wilder-Smith A., Archuleta S., Shek L., Chong C.Y., Nam L.H., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccine Immunother 2012, 8:1259-1271.
27. Tran N.K., Nguyen T.K.T., Wartel T.A., Forrat R., Bouckenooghe A., Saville M. Live, attenuated, tetravalent, CYD dengue vaccine in healthy adults and children: randomized controlled phase II trial in Vietnam. 14th annual conference on vaccine research 2011.
28. Villar L.A., Rivera-Medina D.M., Arredondo-García J.L., Boaz M., Starr-Spires L., Thakur M., et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16-year-olds: a randomized, controlled, Phase II trial in Latin America. Pediatr Infect Dis J 2013, 32:1102-1109.
29. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
30. Roehrig J.T., Hombach J., Barrett A.D.T. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21:123-132.
31. Timiryasova T.M., Bonaparte M.I., Luo P., Zedar R., Hu B.T., Hildreth S.W. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013, 88:962-970.
32. Clopper C., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
33. Newcombe R.G. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998, 17:2635-2650.
34. Teng A.K., Singh S. Epidemiology and new initiatives in the prevention and control of dengue in Malaysia. Dengue Bull 2001, 25:7-14.